Trikafta vs. Orkambi

Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) and Orkambi (lumacaftor/ivacaftor) are combinations CFTR potentiators used to treat cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.

Side effects of Trikafta and Orkambi that are similar include upper respiratory tract infection, diarrhea, rash, runny or stuffy nose, influenza, and increased blood creatine phosphokinase.

Side effects of Trikafta that are different from Orkambi include headache, abdominal pain, sneezing or post-nasal drip, sinusitis, increased alanine aminotransferase, increased aspartate aminotransferase, and increased blood bilirubin.

Side effects of Orkambi that are different from Trikafta include shortness of breath, sore throat, nausea, fatigue, abnormal breathing, gas, menstrual changes, and increases in blood pressure.

Both Trikafta and Orkambi may interact with antifungals, antibiotics, rifampin, rifabutin, seizure medications, St. John's wort, and digoxin.

Trikafta may also interact with glimepiride and glipizide, cyclosporine, everolimus, sirolimus, tacrolimus, statins, glyburide, nateglinide, and repaglinide.

Orkambi may also interact with phenobarbital, benzodiazepines, immunosuppressants, corticosteroids, ibuprofen, antidepressants, hormonal contraceptives, oral hypoglycemics, proton pump inhibitors (PPIs), H2 blockers, antacids, and warfarin.

Common side effects of Trikafta include:

• headache,
• upper respiratory tract infection,
• abdominal pain,
• diarrhea,
• rash,
• increased alanine aminotransferase,
• runny or stuffy nose,
• increased blood creatine phosphokinase,
• increased aspartate aminotransferase,
• sneezing or post-nasal drip,
• influenza,
• sinusitis, and
• increased blood bilirubin

Common side effects of Orkambi include:

• shortness of breath,
• sore throat and stuffy nose (nasopharyngitis),
• nausea,
• diarrhea,
• upper respiratory tract infection,
• fatigue,
• abnormal breathing,
• increased blood creatine phosphokinase,
• rash,
• gas,
• runny nose,
• flu symptoms,
• menstrual changes, and
• increases in blood pressure.

Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor used to treat cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.

Orkambi (lumacaftor/ivacaftor) is a combination of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene.

Trikafta may interact with other medicines such as:

• rifampin,
• rifabutin,
• seizure medications,
• St. John’s wort,
• azole antifungals,
• macrolide antibiotics,
• glimepiride and glipizide,
• digoxin,
• cyclosporine,
• everolimus,
• sirolimus,
• tacrolimus,
• statins,
• glyburide,
• nateglinide, and
• repaglinide

Tell your doctor all medications and supplements you use.

Orkambi may interact with:

• antifungals,
• antibiotics,
• rifampin,
• rifabutin,
• phenobarbital,
• carbamazepine,
• phenytoin,
• St. John's wort,
• benzodiazepines,
• immunosuppressants,
• digoxin,
• corticosteroids,
• ibuprofen, antidepressants,
• hormonal contraceptives,
• oral hypoglycemics,
• proton pump inhibitors (PPIs),
• H2 blockers,
• antacids, and
• warfarin

Tell your doctor all medications and supplements you use.

The morning dose of Trikafta for adults and pediatric patients aged 12 years and older is two elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg tablets. The evening dose of Trikafta for adults and pediatric patients aged 12 years and older is one ivacaftor 150 mg tablet. The morning and evening doses of Trikafta should be taken approximately 12 hours apart with fat-containing food.

The dose of Orkambi for adults and pediatric patients age 12 years and older is two tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) taken orally every 12 hours.